Duopharma Seeking To Diversify Manufacturing Domain

Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech

Morning Run · The Breakfast Grille · 13 Mar 2024 · 26 mins listen

Malaysian pharmaceutical Duopharma Biotech achieved their best financial performance to date in 2022, reaching record highs for revenue and profit. However 2023 was not as kind, with profit after tax falling by 25% despite top line growth. How are they looking to reverse course in 2024? We discuss strategy with Group Managing Director Leonard Ariff Abdul Shatar.

Produced by:

Chin Wai Lun

Presented by:

Shazana Mokhtar

Categories:

sponsored content,medical advances,managing

Tags:

duopharma biotech,pharmaceuticals,market growth

Related Content

GGWP · 18 Nov 2024 · 53 mins

Football Manager - The Beautiful (Video) Game

Daljit Singh, Content Creator, BusttheNet Gaming

Earth Matters · 11 Nov 2024 · 43 mins

Better Drainage in the Fight Against Floods

Liani MK, contributing writer, MacarangaWong Siew Lyn, Editor, MacarangaDr Charles Bong Hin Joo, Hydrology and Urban Drainage Management Researcher, Universiti Malaysia Sarawak (UNIMAS)